CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
Globe Newswire•17/11/2026•16:15 ET
0
Key Highlights
- ➤CytomX (CTMX) achieved a Regeneron preclinical milestone, triggering a $5 million payment.
- ➤Expanded collaboration offers CytomX up to approximately $4 billion in potential milestones.
- ➤Regeneron funds all preclinical and clinical development and commercialization activities.
- ➤Collaboration combines CytomX PROBODY masking with Regeneron Veloci-Bi bispecific technology.
Expert Statements
Sean McCarthy, CEO and Chairman of CytomX
“Achievement of this first milestone from our Regeneron partnership represents the translation of promising science towards the clinic and underscores the potential synergistic approach of combining our respective technologies. Following the expansion of our collaboration in June 2026, we are excited to advance our aligned vision of bringing highly innovative new treatment options to cancer patients”
- The CytomX and Regeneron collaboration began in 2022 and was expanded in June 2026 -
EMERYVILLE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron, triggering a $5 million milestone payment.
Get started
Create a free account to read the full story.
